0000899243-23-020075.txt : 20231031
0000899243-23-020075.hdr.sgml : 20231031
20231031213907
ACCESSION NUMBER: 0000899243-23-020075
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231027
FILED AS OF DATE: 20231031
DATE AS OF CHANGE: 20231031
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ege David S.
CENTRAL INDEX KEY: 0001829360
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 231366338
MAIL ADDRESS:
STREET 1: C/O SERES THERAPEUTICS, INC.
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-27
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001829360
Ege David S.
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
1
Common Stock
2023-10-27
4
M
0
11361
0.00
A
71057
D
Common Stock
2023-10-30
4
S
0
4066
1.35
D
66991
D
Restricted Stock Units
2023-04-27
4
A
0
22721
0.00
A
Common Stock
22721
22721
D
Restricted Stock Units
2023-10-27
4
M
0
11361
0.00
D
Common Stock
11361
11360
D
On February 3, 2023, the reporting person was granted an award of 22,721 RSUs, which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 11,361 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 11,360 RSUs shall vest on October 27, 2024, the date that is eighteen months from the Initial Milestone Date.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 17, 2023, solely with the intent to cover taxes in connection with the vesting of the RSUs.
The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.3425 to $1.405, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date.
Executive Vice President and Chief Technology Officer
/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
2023-10-31